back to Australia directory
australia clinical guidance

Menopause

A detailed Australian summary of menopause, with source-attributed priorities, a practical workflow, safety escalation and state or territory implementation boundaries.

JurisdictionAustralia
Source check2026-08-20
Clinical reviewiatroX editorial team 路 Clinical editorial review 路 reviewed 2026-08-20 路 due 2027-08-20
AudienceHealthcare professionals practising in Australia
This is an iatroX educational summary of named Australia sources, not an official guideline. It does not replace the complete source documents, local policy, specialist advice or clinical judgement. Apply current TGA product information, PBS restrictions, state or territory law, local referral criteria, formulary and antimicrobial policy. A national recommendation does not create uniform service access.

Scope

Diagnose typical perimenopause clinically in the usual age range; reserve hormone testing for premature, early or diagnostically uncertain presentations. Assess vasomotor, sleep, mood, sexual, urogenital and bleeding symptoms together with cardiovascular, bone, breast and thromboembolic risk. This summary is limited to the population, decisions and escalation boundaries stated in the named source.
sources for this section:AMS practitioner menopause toolkit

The Bottom Line

  • Diagnose typical perimenopause clinically in the usual age range; reserve hormone testing for premature, early or diagnostically uncertain presentations.
  • Assess vasomotor, sleep, mood, sexual, urogenital and bleeding symptoms together with cardiovascular, bone, breast and thromboembolic risk.
  • Premature ovarian insufficiency needs confirmation and specialist evaluation of bone, cardiovascular, fertility and genetic or autoimmune context.
  • Discuss menopausal hormone therapy by symptom goal, route, need for endometrial protection, individual contraindications and the lowest effective reviewed regimen.
sources for this section:AMS practitioner menopause toolkit

Practical clinical workflow

1

Topic-specific assessment action

Diagnose typical perimenopause clinically in the usual age range; reserve hormone testing for premature, early or diagnostically uncertain presentations.
2

Topic-specific diagnostic action

Discuss menopausal hormone therapy by symptom goal, route, need for endometrial protection, individual contraindications and the lowest effective reviewed regimen.
3

Topic-specific management action

Use local vaginal oestrogen or non-hormonal measures for genitourinary syndrome when appropriate, and address pelvic-floor and sexual wellbeing.
4

Topic-specific follow-through

Transdermal oestrogen can alter thrombotic risk relative to oral therapy, but individual contraindications and progestogen need still require review.
sources for this section:AMS practitioner menopause toolkit

Safety boundaries and escalation

  • Investigate postmenopausal bleeding and atypical persistent bleeding promptly rather than attributing it to menopause or hormone therapy without assessment.
  • Continue cervical, breast, bowel, cardiovascular and bone prevention according to age and risk rather than stopping prevention after menopause.
sources for this section:AMS practitioner menopause toolkit

Implementation

The named source is national or binational guidance used in Australia, but referral access, public-health directions, formularies and funded services can still differ by state, territory and health service. Check current TGA product information for medicines. Offer culturally safe care and use the NACCHO鈥揜ACGP National Guide where Aboriginal and Torres Strait Islander preventive or chronic-care recommendations differ.
sources for this section:AMS practitioner menopause toolkit

Clinical use boundary

This independently written summary is not an official guideline. Check the linked source version, current TGA-approved product information where medicines are involved, and the applicable state, territory and local pathway at the point of care.

sources for this section:AMS practitioner menopause toolkit

Source documents

Use the linked source documents for complete recommendations, evidence grading, exclusions and implementation detail.

  1. Australasian Menopause Society and Monash University Women鈥檚 Health Research ProgramPractitioner鈥檚 Toolkit for the Management of the Menopause2023 evidence synthesis and algorithms, updated June 2025 路 accessed 2026-08-20
    view source
continue the learning

From guidance to deliberate practice and evidence

Choose what happens next. iatroX can carry this page's jurisdiction, source-check date and released version into an editable learning record, support your reflection, or let you browse the regional question bank while keeping this topic visible. No action records completion, starts a session or awards CPD/CME credit automatically.

Add this guidance review to CPD/CMEOpen an editable learning-log record with this page鈥檚 provenance attached. You confirm the activity, time, reflection and mappings.Reflect on this with TutorUse optional prompts to consider what you learned and what鈥攊f anything鈥攜ou may change. Suggestions are never inserted automatically.Browse the Australia question bankKeep this guidance topic in view, then choose your exam and filters. No session starts automatically.
Found a source update or regional discrepancy? Tell the iatroX editorial team.